News | March 31, 2021
Investment opportunities in India’s healthcare sector: NITI Aayog
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
Integration of various regulatory agencies with a single-window system and putting in place a transparent, stable, predictable and easy to navigate interface.
Zydus has made its brand of Remdesivir, Remdac more affordable at Rs. 899 for a 100 mg lyophilized injection.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
Bharat Biotech expects to share further details of the trial results as additional data become available.
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Applied Biosystems CoviPath COVID-19 RT-PCR Kit is approved for in vitro diagnostic use by ICMR and DCGI.
Subscribe To Our Newsletter & Stay Updated
